Phase 1 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to sign a consent form before any study procedures begin, and who are able to complete all parts of the study as required
- People who are 50 years of age or older at the time of screening
- People who have been diagnosed with a specific type of age-related macular degeneration (AMD) that causes abnormal blood vessel growth in the eye (known as neovascular AMD or nAMD), as confirmed by the lead study doctor
- People who have active abnormal blood vessel growth in the eye related to AMD
- People whose condition has shown a response to a type of eye treatment called anti-VEGF therapy, as assessed by the lead study doctor before joining the study
Who may not be able to join:
- People who have an active infection or active inflammation in or around the study eye at the start of the trial (for example, certain eye infections or conditions affecting the eye surface or inner eye)
- People who have a tear in a specific layer of the eye (the retinal pigment epithelium) in the study eye at the time of screening
- People who currently have bleeding inside the eye (vitreous hemorrhage) in the study eye, or who have had this within the 4 weeks before the trial begins
- People who have any condition that, in the study doctor's opinion, may limit the potential for vision improvement in the study eye
- People who have a history of, or currently have, a detached retina in the study eye
- People who have previously received any form of gene therapy
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Youchen Chen, Peking Union Medical College Hospital
Phone: 13801025972
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Characteristics of dose limiting toxicities (DLTs); Type, severity, and incidence of ocular and systemic adverse events (AEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.